SomaGenics获得NIH资助以开发丁型肝炎治疗药物

StephenW

SomaGenics receives NIH grant to develop hepatitis D therapeutic
July 31, 2018

SomaGenics received a 3-year, $2.9 million award from the National Institutes of Health’s Small Business Innovation Research program to support development of the company’s RNA interference-based approach for hepatitis D, according to a press release.

The company’s HDV therapeutic was designed to simultaneously target the virus at multiple stages of its life cycle using proprietary synthetic short hairpin RNA technology.


The synthetic short hairpin RNA technology are highly potent RNA interference triggers with IC50’s in the low picomolar range. The advantage of SomaGenics’ technology is that they consist of single chemical entities, simplifying their production and purification.

“Our combination, multitarget approach reduces the likelihood of treatment resistance and targets nonhost entities, lowering the chance of toxicity,” Anne Dallas, PhD, and principal scientist with SomaGenics’ HDV program. “We are excited that SomaGenics’ therapeutic may have the potential to cure HDV patients.”

Reference: www.somagenics.com

StephenW

SomaGenics获得NIH资助以开发丁型肝炎治疗药物
2018年7月31日

根据一份新闻稿，SomaGenics从美国国立卫生研究院的小企业创新研究计划获得了一份为期3年，价值290万美元的奖项，以支持该公司基于RNA干扰的丁型肝炎方法的开发。

该公司的HDV治疗剂旨在使用专有的合成短发夹RNA技术在其生命周期的多个阶段同时靶向病毒。


合成的短发夹RNA技术是高效的RNA干扰触发因子，IC50在低皮摩尔范围内。 SomaGenics技术的优势在于它们由单一化学实体组成，简化了它们的生产和纯化。

“我们的组合，多目标方法降低了治疗抵抗的可能性并针对非宿主实体，降低了毒性的机会，”Anne Dallas博士和SomaGenics的HDV项目的首席科学家。 “我们很高兴SomaGenics的治疗方法可能有可能治愈HDV患者。”

参考：www.somagenics.com